About | Free Trial

Last Update

2016-04-12T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Nicholas Cosford?

Dr. Nicholas Cosford D.P.

Professor

Sanford-Burnham Medical Research Institute

Direct Phone: (858) ***-****       

Email: n***@***.org

Sanford-Burnham Medical Research Institute

10901 North Torrey Pines Road

La Jolla, California 92037

United States

Company Description

At Sanford-Burnham, we are dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. With operations in California and Florida, we are one of the fastest-growing research institutes in the coun ... more

Find other employees at this company (971)

Background Information

Employment History

Associate Professor
Burnham Institute

Senior Investigator
Merck & Co. , Inc.

Affiliations

Scientific Advisory Board Member
CalAsia Pharmaceuticals Inc

Education

Ph.D.

Burnham Institute for Medical Research

Web References (64 Total References)


Graduate School Faculty

www.sbpdiscovery.org [cached]

Nicholas Cosford, Ph.D.

Associate Director of Translational Research, NCI-Designated Cancer Center Professor, NCI-Designated Cancer Center
...
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.


Prof. Nicholas Cosford, ...

www.calasiapharma.com [cached]

Prof. Nicholas Cosford, PhD

Dr. Cosford is Professor at Sanford Burnham Medical Research Institute, La Jolla, California. His research is involved in investigating the interactions of small molecule compounds with therapeutically important proteins and cellular signaling pathways. One aspect of his research emphasizes the use of medicinal chemistry and chemical biology approaches to probe intracellular pathways that regulate cell survival and cell growth. Another area of active research is the development of synthetic chemistry methodology using microfluidic technology for the rapid synthesis of biologically active small molecules. Therapeutically, his group is primarily focused on the discovery and optimization of compounds that have the potential to treat cancer, CNS diseases and infectious diseases. He has more than 20 years of experience leading small-molecule drug discovery projects in the pharmaceutical industry. At Sibia Neurosciences and at Merck Research Laboratories he directed multidisciplinary research teams focused on small-molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase. Examples include taking a nicotinic receptor agonist (Altinicline, SIB-1508Y) from initiation of research through to Phase II clinical for PD; taking mGluR5 negative allosteric modulators from HTS hits through in vivo proof-of-concept to Phase I clinical (ongoing); and design, synthesis and optimization of an mGluR5 PET tracer clinical candidate; design, synthesis and optimization of an Akt allosteric inhibitor preclinical candidate. To date, he has published more than 55 peer reviewed scientific publications, has more than 30 issued patents, and more than 30 additional patent applications pending. In 2006 he received the FRAXA Research Foundation Award for Outstanding Contributions to Fragile X Research.


Graduate School Faculty

www.sanfordburnham.org [cached]

Nicholas Cosford, Ph.D.

Professor, NCI-Designated Cancer Center Cell Death and Survival Networks Program
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.


Talent

www.sanfordburnham.org [cached]

Nicholas Cosford, Ph.D.

Professor, NCI-Designated Cancer Center
...
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.


In the accompanying commentary, Allison ...

www.eurekalert.org [cached]

In the accompanying commentary, Allison Limpert and Nicholas Cosford of the Sanford Burnham Institute for Medical Research discus the potential benefits of EEAT2 modulation in treating neurodegenerative disease.

...
AUTHOR CONTACT: Nicholas Cosford Sanford Burnham Institute for Medical Research, San Diego, CA, USA Phone: (858) 795-5316; E-mail: ncosford@sanfordburnham.org
View this article at:http://www.jci.org/articles/view/74608?key=c8cc94ae5cd76270cd4b

Similar Profiles

Other People with this Name

Other people with the name Cosford

Liz Cosford
Butterfly Children's Hospices Foundation Limited

Anne Cosford
Lambton College

Jason Cosford
Saskatchewan Geological Society

Olivia Cosford
Clyde & Co

Paul Cosford
Public Health England

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory